Esperion Therapeutics, Inc. (ESPR) 10-Year Financial Performance & Capital Metrics

ESPR • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

AboutEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Show more

Revenue $332M +185.7%
EBITDA $54M +135.0%
Net Income -$52M +75.3%
EPS (Diluted) -0.28 +86.2%
Gross Margin 79.36% +26.3%
EBITDA Margin 16.39% +112.3%
Operating Margin 16.37% +112.2%
Net Margin -15.57% +91.3%
ROE -
ROIC 132.83%
Debt/Equity -
Interest Coverage 0.92 +134.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Strong 5Y sales CAGR of 17.5%

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 81.5% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y17.5%

3Y61.8%

TTM2.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM14.97%

ROCE

10Y Avg-62.67%

5Y Avg-58.91%

3Y Avg-51.69%

Latest73.94%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	184.47M	148.36M	227.55M	78.45M	75.47M	116.33M	332.31M
Revenue Growth %	-	-	-	-	-0.2%	0.53%	-0.66%	-0.04%	0.54%	1.86%
Cost of Goods Sold+	236K	252K	258K	265K	0	2.39M	14.22M	26.97M	43.27M	68.6M
COGS % of Revenue	-	-	-	0%	-	0.01%	0.18%	0.36%	0.37%	0.21%
Gross Profit+	-236K	-252K	-258K	184.21M	148.36M	225.16M	64.23M	48.51M	73.07M	263.71M
Gross Margin %	-	-	-	1%	1%	0.99%	0.82%	0.64%	0.63%	0.79%
Gross Profit Growth %	-	-0.07%	-0.02%	714.99%	-0.19%	0.52%	-0.71%	-0.24%	0.51%	2.61%
Operating Expenses+	50.04M	76.15M	168.98M	204.59M	241.47M	346.55M	290.96M	228.01M	228.63M	209.31M
OpEx % of Revenue	-	-	-	1.11%	1.63%	1.52%	3.71%	3.02%	1.97%	0.63%
Selling, General & Admin	20.24M	18.28M	21.38M	33.1M	65.85M	199.62M	184.99M	109.08M	142.52M	163.07M
SG&A % of Revenue	-	-	-	0.18%	0.44%	0.88%	2.36%	1.45%	1.23%	0.49%
Research & Development	29.8M	57.87M	147.6M	171.49M	175.61M	146.94M	105.97M	118.93M	86.11M	46.24M
R&D % of Revenue	-	-	-	0.93%	1.18%	0.65%	1.35%	1.58%	0.74%	0.14%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-50.04M	-76.15M	-168.98M	-204.59M	-93.1M	-121.4M	-226.73M	-179.5M	-155.56M	54.4M
Operating Margin %	-	-	-	-1.11%	-0.63%	-0.53%	-2.89%	-2.38%	-1.34%	0.16%
Operating Income Growth %	-0.38%	-0.52%	-1.22%	-0.21%	0.54%	-0.3%	-0.87%	0.21%	0.13%	1.35%
EBITDA+	-49.8M	-75.9M	-168.72M	-204.32M	-92.78M	-120.85M	-226.12M	-179M	-155.4M	54.47M
EBITDA Margin %	-	-	-	-1.11%	-0.63%	-0.53%	-2.88%	-2.37%	-1.34%	0.16%
EBITDA Growth %	-0.38%	-0.52%	-1.22%	-0.21%	0.55%	-0.3%	-0.87%	0.21%	0.13%	1.35%
D&A (Non-Cash Add-back)	236K	252K	258K	265K	319K	547K	612K	500K	164K	63K
EBIT	-49.26M	-74.6M	-166.79M	-204.59M	-89.05M	-120.88M	-222.75M	-176.85M	-150.27M	7.51M
Net Interest Income+	0	0	0	0	-8.12M	-22.67M	-46.35M	-56.81M	-58.98M	-59.25M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	520K	376K	198K	100K	8.12M	22.67M	46.35M	56.81M	58.98M	59.25M
Other Income/Expense	256K	1.17M	1.99M	2.77M	-4.06M	-22.16M	-42.38M	-54.16M	-53.69M	-106.15M
Pretax Income+	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Pretax Margin %	-	-	-	-1.09%	-0.65%	-0.63%	-3.43%	-3.1%	-1.8%	-0.16%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Net Margin %	-	-	-	-1.09%	-0.65%	-0.63%	-3.43%	-3.1%	-1.8%	-0.16%
Net Income Growth %	-0.37%	-0.51%	-1.23%	-0.21%	0.52%	-0.48%	-0.87%	0.13%	0.1%	0.75%
Net Income (Continuing)	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.26	-3.33	-6.98	-7.54	-4.02	-6.05	-11.03	-4.33	-2.03	-0.28
EPS Growth %	-0.02%	-0.47%	-1.1%	-0.08%	0.47%	-0.5%	-0.82%	0.61%	0.53%	0.86%
EPS (Basic)	-2.26	-3.33	-6.98	-7.54	-4.02	-6.05	-11.03	-4.33	-2.03	-0.28
Diluted Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	28.9M	66.41M	103.11M	187.18M
Basic Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	28.9M	66.41M	103.11M	187.18M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	214.39M	213.58M	203.92M	142.63M	211.71M	345.9M	328.97M	246.68M	201.06M	338M
Cash & Short-Term Investments	77.34M	38.16M	34.47M	36.97M	200.78M	304.96M	259.33M	166.86M	82.25M	144.76M
Cash Only	77.34M	38.16M	34.47M	36.97M	166.13M	304.96M	208.89M	124.78M	82.25M	144.76M
Short-Term Investments	0	0	0	0	34.65M	0	50.44M	42.09M	0	0
Accounts Receivable	0	0	0	0	0	12.39M	22.93M	33.73M	48.49M	80.14M
Days Sales Outstanding	-	-	-	-	-	19.87	106.71	163.11	152.15	88.02
Inventory	0	0	0	0	0	16.14M	34.39M	35.2M	65.62M	94.49M
Days Inventory Outstanding	-	-	-	-	-	2.46K	883.01	476.45	553.6	502.75
Other Current Assets	0	0	0	0	928K	0	11.17M	9.87M	4.51M	18.02M
Total Non-Current Assets+	81.18M	31.64M	73.91M	819K	2.73M	7.36M	52.62M	1.26M	4.73M	5.82M
Property, Plant & Equipment	807K	674K	435K	520K	2.68M	7.31M	2.56M	1.2M	4.67M	5.77M
Fixed Asset Turnover	-	-	-	354.76x	55.42x	31.15x	30.62x	62.90x	24.88x	57.62x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	56K	56K	56K	56K	56K	56K	0	0	56K	56K
Long-Term Investments	215.24M	204.32M	239.15M	99.29M	0	0	0	0	0	0
Other Non-Current Assets	-134.93M	-173.42M	-165.73M	-99.05M	0	0	50M	0	0	0
Total Assets+	295.57M	245.21M	277.83M	143.45M	214.45M	353.26M	381.59M	247.94M	205.8M	343.82M
Asset Turnover	-	-	-	1.29x	0.69x	0.64x	0.21x	0.30x	0.57x	0.97x
Asset Growth %	1.06%	-0.17%	0.13%	-0.48%	0.49%	0.65%	0.08%	-0.35%	-0.17%	0.67%
Total Current Liabilities+	5.63M	15.59M	33.14M	64.33M	66.08M	94.07M	73.35M	92.31M	156.22M	246.23M
Accounts Payable	707K	4.59M	20.38M	44.89M	28.86M	51.98M	17.56M	23.04M	31.72M	51.65M
Days Payables Outstanding	1.09K	6.66K	28.83K	61.83K	-	7.93K	450.8	311.85	267.57	274.81
Short-Term Debt	1.6M	1.71M	1.04M	0	0	0	0	0	34.83M	102.16M
Deferred Revenue (Current)	37K	40K	38K	0	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	0	10.99M	1.88M	7.82M	15.16M	8.81M	9.05M	49.24M	12.74M
Current Ratio	38.11x	13.70x	6.15x	2.22x	3.20x	3.68x	4.48x	2.67x	1.29x	1.37x
Quick Ratio	38.11x	13.70x	6.15x	2.22x	3.20x	3.51x	4.02x	2.29x	0.87x	0.99x
Cash Conversion Cycle	-	-	-	-	-	-5.45K	538.92	327.71	438.17	315.97
Total Non-Current Liabilities+	2.69M	1.02M	0	0	128.42M	355.32M	505.18M	479.41M	504.57M	486.31M
Long-Term Debt	2.69M	1.02M	0	0	0	179.37M	258.28M	259.9M	501.55M	483.74M
Capital Lease Obligations	0	0	0	0	1.11M	3.45M	524K	665K	3.02M	2.57M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	127.31M	172.5M	245.74M	218.84M	0	0
Total Liabilities	8.31M	16.61M	33.14M	64.33M	194.5M	449.39M	578.53M	571.72M	660.79M	732.54M
Total Debt+	4.29M	2.73M	1.04M	0	1.56M	185.41M	260.2M	260.95M	540.95M	591.21M
Net Debt	-73.04M	-35.43M	-33.42M	-36.97M	-164.57M	-119.55M	51.3M	136.17M	458.7M	446.45M
Debt / Equity	0.01x	0.01x	0.00x	-	0.08x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	10.85x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	8.20x
Interest Coverage	-96.23x	-202.53x	-853.44x	-2045.85x	-11.47x	-5.35x	-4.89x	-3.16x	-2.64x	0.92x
Total Equity+	287.26M	228.6M	244.69M	-598.1M	19.95M	-96.13M	-196.94M	-323.78M	-454.99M	-388.72M
Equity Growth %	1.15%	-0.2%	0.07%	-3.44%	1.03%	-5.82%	-1.05%	-0.64%	-0.41%	0.15%
Book Value per Share	13.05	10.14	10.22	-22.36	0.74	-3.50	-6.81	-4.88	-4.41	-2.08
Total Shareholders' Equity	287.26M	228.6M	244.69M	-598.1M	19.95M	-96.13M	-196.94M	-323.78M	-454.99M	-388.72M
Common Stock	23K	23K	26K	27K	27K	26K	61K	75K	118K	196K
Retained Earnings	-154.22M	-229.2M	-396.29M	-598.1M	-695.27M	-838.82M	-1.11B	-1.34B	-1.55B	-1.6B
Treasury Stock	0	0	0	0	0	-55M	-55M	-55M	-55M	-55M
Accumulated OCI	-482K	-172K	-845K	-319K	23K	0	-31K	-2K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38.16M	-47.73M	-131.3M	-148.64M	-70.34M	-85.18M	-263.81M	-174.83M	-135.49M	-23.65M
Operating CF Margin %	-	-	-	-0.81%	-0.47%	-0.37%	-3.36%	-2.32%	-1.16%	-0.07%
Operating CF Growth %	-0.19%	-0.25%	-1.75%	-0.13%	0.53%	-0.21%	-2.1%	0.34%	0.23%	0.83%
Net Income	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Depreciation & Amortization	236K	252K	258K	265K	319K	547K	612K	500K	164K	63K
Stock-Based Compensation	12.73M	15.96M	18.61M	23.97M	25.88M	28.39M	24.31M	15.21M	11.96M	11.99M
Deferred Taxes	694K	1.01M	334K	0	0	-97K	0	0	0	0
Other Non-Cash Items	61K	44K	23K	-217K	7.92M	33.8M	32.89M	46.49M	47.96M	76.56M
Working Capital Changes	-2.09M	9.98M	16.47M	29.16M	-7.3M	-4.26M	-52.51M	-3.37M	13.68M	-60.53M
Change in Receivables	0	0	0	0	0	-10.74M	-10.55M	-10.79M	-14.77M	-31.65M
Change in Inventory	0	0	0	0	0	-16.14M	-18.26M	-807K	-30.42M	-28.87M
Change in Payables	-1.33M	3.89M	15.76M	24.45M	-16.05M	23.11M	-34.1M	5.6M	8.68M	12.43M
Cash from Investing+	-160.07M	10.12M	-35.85M	140.45M	64.23M	21.36M	-50.48M	8.1M	42.5M	-317K
Capital Expenditures	-325K	-94K	-19K	-151K	-953K	-13.37M	0	0	0	-317K
CapEx % of Revenue	-	-	-	0%	0.01%	0.06%	-	-	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	24K	10.21M	-35.83M	140.6M	0	-12.5M	0	0	0	0
Cash from Financing+	190.52M	-1.56M	163.46M	10.69M	136.19M	201.72M	268.22M	32.61M	50.46M	86.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.18M	45K	1.17M	11.74M	136.19M	-14.87M	49.98M	-58.24M	-6.42M	-39.72M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-38.48M	-47.82M	-131.32M	-148.79M	-71.29M	-98.55M	-263.81M	-174.83M	-135.49M	-23.97M
FCF Margin %	-	-	-	-0.81%	-0.48%	-0.43%	-3.36%	-2.32%	-1.16%	-0.07%
FCF Growth %	-0.17%	-0.24%	-1.75%	-0.13%	0.52%	-0.38%	-1.68%	0.34%	0.23%	0.82%
FCF per Share	-1.75	-2.12	-5.49	-5.56	-2.63	-3.59	-9.13	-2.63	-1.31	-0.13
FCF Conversion (FCF/Net Income)	0.77x	0.64x	0.79x	0.74x	0.72x	0.59x	0.98x	0.75x	0.65x	0.46x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-23.66%	-29.07%	-70.56%	-	-487.04%	-	-	-	-	-
Return on Invested Capital (ROIC)	-28.04%	-28.04%	-62.67%	-	-	-	-	-	-	132.83%
Gross Margin	-	-	-	99.86%	100%	98.95%	81.88%	64.27%	62.81%	79.36%
Net Margin	-	-	-	-109.4%	-65.49%	-63.09%	-343.04%	-309.58%	-179.87%	-15.57%
Debt / Equity	0.01x	0.01x	0.00x	-	0.08x	-	-	-	-	-
Interest Coverage	-96.23x	-202.53x	-853.44x	-2045.85x	-11.47x	-5.35x	-4.89x	-3.16x	-2.64x	0.92x
FCF Conversion	0.77x	0.64x	0.79x	0.74x	0.72x	0.59x	0.98x	0.75x	0.65x	0.46x
Revenue Growth	-	-	-	-	-19.57%	53.37%	-65.52%	-3.79%	54.14%	185.66%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Collaboration Revenue	-	214.58M	38.4M	19.61M	38M	216.59M
Collaboration Revenue Growth	-	-	-82.10%	-48.93%	93.75%	469.99%
Product	-	-	40.05M	55.86M	78.33M	115.72M
Product Growth	-	-	-	39.49%	40.23%	47.73%
Milestone Marketing Authorization Approval Nustendi	-	150M	-	-	-	-
Milestone Marketing Authorization Approval Nustendi Growth	-	-	-	-	-	-
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi	-	2.8M	-	-	-	-
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi Growth	-	-	-	-	-	-
Ongoing Regulatory And Development Activities Revenue	4M	1.6M	-	-	-	-
Ongoing Regulatory And Development Activities Revenue Growth	-	-60.00%	-	-	-	-
License For Intellectual Property Revenue	144.4M	-	-	-	-	-
License For Intellectual Property Revenue Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Esperion Therapeutics, Inc. (ESPR) reported $303.8M in revenue for fiscal year 2024.

Esperion Therapeutics, Inc. (ESPR) grew revenue by 185.7% over the past year. This is strong growth.

Esperion Therapeutics, Inc. (ESPR) reported a net loss of $105.8M for fiscal year 2024.

Dividend & Returns

Esperion Therapeutics, Inc. (ESPR) had negative free cash flow of $93.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Esperion Therapeutics, Inc. (ESPR) 10-Year Financial Performance & Capital Metrics

ESPR • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

Revenue $332M +185.7%
EBITDA $54M +135.0%
Net Income -$52M +75.3%
EPS (Diluted) -0.28 +86.2%
Gross Margin 79.36% +26.3%
EBITDA Margin 16.39% +112.3%
Operating Margin 16.37% +112.2%
Net Margin -15.57% +91.3%
ROE -
ROIC 132.83%
Debt/Equity -
Interest Coverage 0.92 +134.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Strong 5Y sales CAGR of 17.5%

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 81.5% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y17.5%

3Y61.8%

TTM2.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM14.97%

ROCE

10Y Avg-62.67%

5Y Avg-58.91%

3Y Avg-51.69%

Latest73.94%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	184.47M	148.36M	227.55M	78.45M	75.47M	116.33M	332.31M
Revenue Growth %	-	-	-	-	-0.2%	0.53%	-0.66%	-0.04%	0.54%	1.86%
Cost of Goods Sold+	236K	252K	258K	265K	0	2.39M	14.22M	26.97M	43.27M	68.6M
COGS % of Revenue	-	-	-	0%	-	0.01%	0.18%	0.36%	0.37%	0.21%
Gross Profit+	-236K	-252K	-258K	184.21M	148.36M	225.16M	64.23M	48.51M	73.07M	263.71M
Gross Margin %	-	-	-	1%	1%	0.99%	0.82%	0.64%	0.63%	0.79%
Gross Profit Growth %	-	-0.07%	-0.02%	714.99%	-0.19%	0.52%	-0.71%	-0.24%	0.51%	2.61%
Operating Expenses+	50.04M	76.15M	168.98M	204.59M	241.47M	346.55M	290.96M	228.01M	228.63M	209.31M
OpEx % of Revenue	-	-	-	1.11%	1.63%	1.52%	3.71%	3.02%	1.97%	0.63%
Selling, General & Admin	20.24M	18.28M	21.38M	33.1M	65.85M	199.62M	184.99M	109.08M	142.52M	163.07M
SG&A % of Revenue	-	-	-	0.18%	0.44%	0.88%	2.36%	1.45%	1.23%	0.49%
Research & Development	29.8M	57.87M	147.6M	171.49M	175.61M	146.94M	105.97M	118.93M	86.11M	46.24M
R&D % of Revenue	-	-	-	0.93%	1.18%	0.65%	1.35%	1.58%	0.74%	0.14%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-50.04M	-76.15M	-168.98M	-204.59M	-93.1M	-121.4M	-226.73M	-179.5M	-155.56M	54.4M
Operating Margin %	-	-	-	-1.11%	-0.63%	-0.53%	-2.89%	-2.38%	-1.34%	0.16%
Operating Income Growth %	-0.38%	-0.52%	-1.22%	-0.21%	0.54%	-0.3%	-0.87%	0.21%	0.13%	1.35%
EBITDA+	-49.8M	-75.9M	-168.72M	-204.32M	-92.78M	-120.85M	-226.12M	-179M	-155.4M	54.47M
EBITDA Margin %	-	-	-	-1.11%	-0.63%	-0.53%	-2.88%	-2.37%	-1.34%	0.16%
EBITDA Growth %	-0.38%	-0.52%	-1.22%	-0.21%	0.55%	-0.3%	-0.87%	0.21%	0.13%	1.35%
D&A (Non-Cash Add-back)	236K	252K	258K	265K	319K	547K	612K	500K	164K	63K
EBIT	-49.26M	-74.6M	-166.79M	-204.59M	-89.05M	-120.88M	-222.75M	-176.85M	-150.27M	7.51M
Net Interest Income+	0	0	0	0	-8.12M	-22.67M	-46.35M	-56.81M	-58.98M	-59.25M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	520K	376K	198K	100K	8.12M	22.67M	46.35M	56.81M	58.98M	59.25M
Other Income/Expense	256K	1.17M	1.99M	2.77M	-4.06M	-22.16M	-42.38M	-54.16M	-53.69M	-106.15M
Pretax Income+	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Pretax Margin %	-	-	-	-1.09%	-0.65%	-0.63%	-3.43%	-3.1%	-1.8%	-0.16%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Net Margin %	-	-	-	-1.09%	-0.65%	-0.63%	-3.43%	-3.1%	-1.8%	-0.16%
Net Income Growth %	-0.37%	-0.51%	-1.23%	-0.21%	0.52%	-0.48%	-0.87%	0.13%	0.1%	0.75%
Net Income (Continuing)	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.26	-3.33	-6.98	-7.54	-4.02	-6.05	-11.03	-4.33	-2.03	-0.28
EPS Growth %	-0.02%	-0.47%	-1.1%	-0.08%	0.47%	-0.5%	-0.82%	0.61%	0.53%	0.86%
EPS (Basic)	-2.26	-3.33	-6.98	-7.54	-4.02	-6.05	-11.03	-4.33	-2.03	-0.28
Diluted Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	28.9M	66.41M	103.11M	187.18M
Basic Shares Outstanding	22.02M	22.54M	23.93M	26.75M	27.09M	27.47M	28.9M	66.41M	103.11M	187.18M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	214.39M	213.58M	203.92M	142.63M	211.71M	345.9M	328.97M	246.68M	201.06M	338M
Cash & Short-Term Investments	77.34M	38.16M	34.47M	36.97M	200.78M	304.96M	259.33M	166.86M	82.25M	144.76M
Cash Only	77.34M	38.16M	34.47M	36.97M	166.13M	304.96M	208.89M	124.78M	82.25M	144.76M
Short-Term Investments	0	0	0	0	34.65M	0	50.44M	42.09M	0	0
Accounts Receivable	0	0	0	0	0	12.39M	22.93M	33.73M	48.49M	80.14M
Days Sales Outstanding	-	-	-	-	-	19.87	106.71	163.11	152.15	88.02
Inventory	0	0	0	0	0	16.14M	34.39M	35.2M	65.62M	94.49M
Days Inventory Outstanding	-	-	-	-	-	2.46K	883.01	476.45	553.6	502.75
Other Current Assets	0	0	0	0	928K	0	11.17M	9.87M	4.51M	18.02M
Total Non-Current Assets+	81.18M	31.64M	73.91M	819K	2.73M	7.36M	52.62M	1.26M	4.73M	5.82M
Property, Plant & Equipment	807K	674K	435K	520K	2.68M	7.31M	2.56M	1.2M	4.67M	5.77M
Fixed Asset Turnover	-	-	-	354.76x	55.42x	31.15x	30.62x	62.90x	24.88x	57.62x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	56K	56K	56K	56K	56K	56K	0	0	56K	56K
Long-Term Investments	215.24M	204.32M	239.15M	99.29M	0	0	0	0	0	0
Other Non-Current Assets	-134.93M	-173.42M	-165.73M	-99.05M	0	0	50M	0	0	0
Total Assets+	295.57M	245.21M	277.83M	143.45M	214.45M	353.26M	381.59M	247.94M	205.8M	343.82M
Asset Turnover	-	-	-	1.29x	0.69x	0.64x	0.21x	0.30x	0.57x	0.97x
Asset Growth %	1.06%	-0.17%	0.13%	-0.48%	0.49%	0.65%	0.08%	-0.35%	-0.17%	0.67%
Total Current Liabilities+	5.63M	15.59M	33.14M	64.33M	66.08M	94.07M	73.35M	92.31M	156.22M	246.23M
Accounts Payable	707K	4.59M	20.38M	44.89M	28.86M	51.98M	17.56M	23.04M	31.72M	51.65M
Days Payables Outstanding	1.09K	6.66K	28.83K	61.83K	-	7.93K	450.8	311.85	267.57	274.81
Short-Term Debt	1.6M	1.71M	1.04M	0	0	0	0	0	34.83M	102.16M
Deferred Revenue (Current)	37K	40K	38K	0	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	0	10.99M	1.88M	7.82M	15.16M	8.81M	9.05M	49.24M	12.74M
Current Ratio	38.11x	13.70x	6.15x	2.22x	3.20x	3.68x	4.48x	2.67x	1.29x	1.37x
Quick Ratio	38.11x	13.70x	6.15x	2.22x	3.20x	3.51x	4.02x	2.29x	0.87x	0.99x
Cash Conversion Cycle	-	-	-	-	-	-5.45K	538.92	327.71	438.17	315.97
Total Non-Current Liabilities+	2.69M	1.02M	0	0	128.42M	355.32M	505.18M	479.41M	504.57M	486.31M
Long-Term Debt	2.69M	1.02M	0	0	0	179.37M	258.28M	259.9M	501.55M	483.74M
Capital Lease Obligations	0	0	0	0	1.11M	3.45M	524K	665K	3.02M	2.57M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	127.31M	172.5M	245.74M	218.84M	0	0
Total Liabilities	8.31M	16.61M	33.14M	64.33M	194.5M	449.39M	578.53M	571.72M	660.79M	732.54M
Total Debt+	4.29M	2.73M	1.04M	0	1.56M	185.41M	260.2M	260.95M	540.95M	591.21M
Net Debt	-73.04M	-35.43M	-33.42M	-36.97M	-164.57M	-119.55M	51.3M	136.17M	458.7M	446.45M
Debt / Equity	0.01x	0.01x	0.00x	-	0.08x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	10.85x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	8.20x
Interest Coverage	-96.23x	-202.53x	-853.44x	-2045.85x	-11.47x	-5.35x	-4.89x	-3.16x	-2.64x	0.92x
Total Equity+	287.26M	228.6M	244.69M	-598.1M	19.95M	-96.13M	-196.94M	-323.78M	-454.99M	-388.72M
Equity Growth %	1.15%	-0.2%	0.07%	-3.44%	1.03%	-5.82%	-1.05%	-0.64%	-0.41%	0.15%
Book Value per Share	13.05	10.14	10.22	-22.36	0.74	-3.50	-6.81	-4.88	-4.41	-2.08
Total Shareholders' Equity	287.26M	228.6M	244.69M	-598.1M	19.95M	-96.13M	-196.94M	-323.78M	-454.99M	-388.72M
Common Stock	23K	23K	26K	27K	27K	26K	61K	75K	118K	196K
Retained Earnings	-154.22M	-229.2M	-396.29M	-598.1M	-695.27M	-838.82M	-1.11B	-1.34B	-1.55B	-1.6B
Treasury Stock	0	0	0	0	0	-55M	-55M	-55M	-55M	-55M
Accumulated OCI	-482K	-172K	-845K	-319K	23K	0	-31K	-2K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38.16M	-47.73M	-131.3M	-148.64M	-70.34M	-85.18M	-263.81M	-174.83M	-135.49M	-23.65M
Operating CF Margin %	-	-	-	-0.81%	-0.47%	-0.37%	-3.36%	-2.32%	-1.16%	-0.07%
Operating CF Growth %	-0.19%	-0.25%	-1.75%	-0.13%	0.53%	-0.21%	-2.1%	0.34%	0.23%	0.83%
Net Income	-49.78M	-74.98M	-166.99M	-201.81M	-97.17M	-143.55M	-269.11M	-233.66M	-209.25M	-51.74M
Depreciation & Amortization	236K	252K	258K	265K	319K	547K	612K	500K	164K	63K
Stock-Based Compensation	12.73M	15.96M	18.61M	23.97M	25.88M	28.39M	24.31M	15.21M	11.96M	11.99M
Deferred Taxes	694K	1.01M	334K	0	0	-97K	0	0	0	0
Other Non-Cash Items	61K	44K	23K	-217K	7.92M	33.8M	32.89M	46.49M	47.96M	76.56M
Working Capital Changes	-2.09M	9.98M	16.47M	29.16M	-7.3M	-4.26M	-52.51M	-3.37M	13.68M	-60.53M
Change in Receivables	0	0	0	0	0	-10.74M	-10.55M	-10.79M	-14.77M	-31.65M
Change in Inventory	0	0	0	0	0	-16.14M	-18.26M	-807K	-30.42M	-28.87M
Change in Payables	-1.33M	3.89M	15.76M	24.45M	-16.05M	23.11M	-34.1M	5.6M	8.68M	12.43M
Cash from Investing+	-160.07M	10.12M	-35.85M	140.45M	64.23M	21.36M	-50.48M	8.1M	42.5M	-317K
Capital Expenditures	-325K	-94K	-19K	-151K	-953K	-13.37M	0	0	0	-317K
CapEx % of Revenue	-	-	-	0%	0.01%	0.06%	-	-	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	24K	10.21M	-35.83M	140.6M	0	-12.5M	0	0	0	0
Cash from Financing+	190.52M	-1.56M	163.46M	10.69M	136.19M	201.72M	268.22M	32.61M	50.46M	86.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.18M	45K	1.17M	11.74M	136.19M	-14.87M	49.98M	-58.24M	-6.42M	-39.72M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-38.48M	-47.82M	-131.32M	-148.79M	-71.29M	-98.55M	-263.81M	-174.83M	-135.49M	-23.97M
FCF Margin %	-	-	-	-0.81%	-0.48%	-0.43%	-3.36%	-2.32%	-1.16%	-0.07%
FCF Growth %	-0.17%	-0.24%	-1.75%	-0.13%	0.52%	-0.38%	-1.68%	0.34%	0.23%	0.82%
FCF per Share	-1.75	-2.12	-5.49	-5.56	-2.63	-3.59	-9.13	-2.63	-1.31	-0.13
FCF Conversion (FCF/Net Income)	0.77x	0.64x	0.79x	0.74x	0.72x	0.59x	0.98x	0.75x	0.65x	0.46x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-23.66%	-29.07%	-70.56%	-	-487.04%	-	-	-	-	-
Return on Invested Capital (ROIC)	-28.04%	-28.04%	-62.67%	-	-	-	-	-	-	132.83%
Gross Margin	-	-	-	99.86%	100%	98.95%	81.88%	64.27%	62.81%	79.36%
Net Margin	-	-	-	-109.4%	-65.49%	-63.09%	-343.04%	-309.58%	-179.87%	-15.57%
Debt / Equity	0.01x	0.01x	0.00x	-	0.08x	-	-	-	-	-
Interest Coverage	-96.23x	-202.53x	-853.44x	-2045.85x	-11.47x	-5.35x	-4.89x	-3.16x	-2.64x	0.92x
FCF Conversion	0.77x	0.64x	0.79x	0.74x	0.72x	0.59x	0.98x	0.75x	0.65x	0.46x
Revenue Growth	-	-	-	-	-19.57%	53.37%	-65.52%	-3.79%	54.14%	185.66%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Collaboration Revenue	-	214.58M	38.4M	19.61M	38M	216.59M
Collaboration Revenue Growth	-	-	-82.10%	-48.93%	93.75%	469.99%
Product	-	-	40.05M	55.86M	78.33M	115.72M
Product Growth	-	-	-	39.49%	40.23%	47.73%
Milestone Marketing Authorization Approval Nustendi	-	150M	-	-	-	-
Milestone Marketing Authorization Approval Nustendi Growth	-	-	-	-	-	-
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi	-	2.8M	-	-	-	-
Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi Growth	-	-	-	-	-	-
Ongoing Regulatory And Development Activities Revenue	4M	1.6M	-	-	-	-
Ongoing Regulatory And Development Activities Revenue Growth	-	-60.00%	-	-	-	-
License For Intellectual Property Revenue	144.4M	-	-	-	-	-
License For Intellectual Property Revenue Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Esperion Therapeutics, Inc. (ESPR) reported $303.8M in revenue for fiscal year 2024.

Esperion Therapeutics, Inc. (ESPR) grew revenue by 185.7% over the past year. This is strong growth.

Esperion Therapeutics, Inc. (ESPR) reported a net loss of $105.8M for fiscal year 2024.

Dividend & Returns

Esperion Therapeutics, Inc. (ESPR) had negative free cash flow of $93.3M in fiscal year 2024, likely due to heavy capital investments.